TD Asset Management Inc Buys 95,777 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Key Points

• TD Asset Management Inc increased its holdings in Cellebrite DI Ltd. by 909.6% during the first quarter, owning 106,306 shares valued at approximately $2.06 million.
• Cellebrite DI reported a quarterly earnings per share of $0.10, surpassing analysts' expectations of $0.09, with total revenue of $107.55 million for the quarter.
• Research analysts have mixed opinions on Cellebrite DI, with JPMorgan Chase reducing its price target from $29.00 to $25.00 while other ratings generally maintain an average of "Moderate Buy" with a target price of approximately $22.43.

TD Asset Management Inc increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 909.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,306 shares of the company's stock after purchasing an additional 95,777 shares during the period. TD Asset Management Inc's holdings in Cellebrite DI were worth $2,066,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of CLBT. KLP Kapitalforvaltning AS acquired a new position in shares of Cellebrite DI during the fourth quarter worth $308,000. LPL Financial LLC grew its stake in shares of Cellebrite DI by 39.0% during the fourth quarter. LPL Financial LLC now owns 54,402 shares of the company's stock worth $1,198,000 after purchasing an additional 15,267 shares in the last quarter. Pictet Asset Management Holding SA acquired a new position in shares of Cellebrite DI during the fourth quarter worth $283,000. Alliancebernstein L.P. raised its stake in Cellebrite DI by 109.7% during the 4th quarter. Alliancebernstein L.P. now owns 28,633 shares of the company's stock worth $631,000 after acquiring an additional 14,981 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Cellebrite DI by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 246,262 shares of the company's stock worth $5,425,000 after acquiring an additional 6,994 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Up 0.8%

NASDAQ CLBT traded up $0.11 during trading hours on Wednesday, reaching $13.76. 437,832 shares of the company traded hands, compared to its average volume of 1,564,565. The company has a 50 day moving average of $15.37 and a two-hundred day moving average of $18.29. Cellebrite DI Ltd. has a 12 month low of $12.63 and a 12 month high of $26.30. The stock has a market capitalization of $3.30 billion, a PE ratio of -14.33, a PEG ratio of 2.75 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same quarter last year, the company earned $0.08 EPS. The company's revenue for the quarter was up 20.0% compared to the same quarter last year. On average, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

CLBT has been the topic of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of Cellebrite DI in a research note on Friday, June 6th. Wall Street Zen lowered shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.